Graham Richard A.'s Insider Trades & SAST Disclosures
Graham Richard A.'s most recent trade in Theravance Biopharma Inc was a trade of 19,294 Ordinary Shares done at an average price of $8.9 . Disclosure was reported to the exchange on Feb. 20, 2024.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Graham Richard A..To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Theravance Biopharma Inc | Graham Richard A. | SVP, RESEARCH & DEVELOPMENT | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.92 per share. | 20 Feb 2024 | 19,294 | 314,915 (0%) | 0% | 8.9 | 172,102 | Ordinary Shares |
| Theravance Biopharma Inc | Richard A. Graham | SVP, RESEARCH & DEVELOPMENT | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.70 per share. | 20 Aug 2023 | 10,461 | 339,285 (0%) | 0% | 9.7 | 101,472 | Ordinary Shares |
| Theravance Biopharma Inc | Richard A. Graham | SVP, RESEARCH & DEVELOPMENT | Sale of securities on an exchange or to another person at price $ 9.99 per share. | 11 Aug 2023 | 2,322 | 349,746 (0%) | 0% | 10.0 | 23,197 | Ordinary Shares |
| Theravance Biopharma Inc | Richard A. Graham | SVP, RESEARCH & DEVELOPMENT | Sale of securities on an exchange or to another person at price $ 9.84 per share. | 14 Jul 2023 | 2,322 | 352,068 (0%) | 0% | 9.8 | 22,848 | Ordinary Shares |
| Theravance Biopharma Inc | Richard A. Graham | SVP, RESEARCH & DEVELOPMENT | Sale of securities on an exchange or to another person at price $ 10.69 per share. | 14 Jun 2023 | 2,322 | 354,390 (0%) | 0% | 10.7 | 24,822 | Ordinary Shares |
| Theravance Biopharma Inc | Richard A. Graham | SVP, RESEARCH & DEVELOPMENT | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.21 per share. | 20 May 2023 | 10,460 | 356,712 (0%) | 0% | 11.2 | 117,257 | Ordinary Shares |
| Theravance Biopharma Inc | Richard A. Graham | SVP, RESEARCH & DEVELOPMENT | Sale of securities on an exchange or to another person at price $ 11.26 per share. | 15 May 2023 | 2,322 | 367,172 (0%) | 0% | 11.3 | 26,146 | Ordinary Shares |
| Theravance Biopharma Inc | Richard A. Graham | SVP, RESEARCH & DEVELOPMENT | Sale of securities on an exchange or to another person at price $ 11.88 per share. | 14 Apr 2023 | 2,323 | 369,494 (0%) | 0% | 11.9 | 27,597 | Ordinary Shares |
| Theravance Biopharma Inc | Richard A. Graham | SVP, RESEARCH & DEVELOPMENT | Sale of securities on an exchange or to another person at price $ 10.32 per share. | 14 Mar 2023 | 2,323 | 371,817 (0%) | 0% | 10.3 | 23,973 | Ordinary Shares |
| Theravance Biopharma Inc | Richard A. Graham | SVP, RESEARCH & DEVELOPMENT | Sale of securities on an exchange or to another person at price $ 10.05 per share. | 06 Mar 2023 | 2,323 | 374,140 (0%) | 0% | 10.0 | 23,346 | Ordinary Shares |
| Theravance Biopharma Inc | Richard A. Graham | SVP, RESEARCH & DEVELOPMENT | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 75,000 | 376,463 (0%) | 0% | 0 | Ordinary Shares | |
| Theravance Biopharma Inc | Richard A. Graham | SVP, RESEARCH & DEVELOPMENT | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.44 per share. | 20 Feb 2023 | 12,057 | 301,463 (0%) | 0% | 10.4 | 125,875 | Ordinary Shares |
| Theravance Biopharma Inc | Richard A. Graham | SVP, RESEARCH & DEVELOPMENT | Sale of securities on an exchange or to another person at price $ 10.73 per share. | 01 Dec 2022 | 2,084 | 313,520 (0%) | 0% | 10.7 | 22,361 | Ordinary Shares |
| Theravance Biopharma Inc | Richard A. Graham | SVP, RESEARCH & DEVELOPMENT | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.85 per share. | 20 Nov 2022 | 27,350 | 315,604 (0%) | 0% | 10.9 | 296,748 | Ordinary Shares |
| Theravance Biopharma Inc | Richard A. Graham | SVP, RESEARCH & DEVELOPMENT | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.20 per share. | 16 Nov 2022 | 2,800 | 342,954 (0%) | 0% | 11.2 | 31,360 | Ordinary Shares |
| Theravance Biopharma Inc | Richard A. Graham | SVP, DEVELOPMENT | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.34 per share. | 19 Aug 2022 | 18,991 | 345,754 (0%) | 0% | 9.3 | 177,376 | Ordinary Shares |
| Theravance Biopharma Inc | Richard A. Graham | SVP, DEVELOPMENT | Sale of securities on an exchange or to another person at price $ 9.71 per share. | 16 Aug 2022 | 4,906 | 364,745 (0%) | 0% | 9.7 | 47,640 | Ordinary Shares |
| Theravance Biopharma Inc | Richard A. Graham | SVP, DEVELOPMENT | Sale of securities on an exchange or to another person at price $ 8.79 per share. | 09 Aug 2022 | 15,086 | 369,651 (0%) | 0% | 8.8 | 132,606 | Ordinary Shares |
| Theravance Biopharma Inc | Richard A. Graham | SVP, DEVELOPMENT | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.74 per share. | 20 May 2022 | 3,947 | 384,737 (0%) | 0% | 8.7 | 34,497 | Ordinary Shares |
| Theravance Biopharma Inc | Richard A. Graham | SVP, DEVELOPMENT | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.61 per share. | 18 Feb 2022 | 20,377 | 388,684 (0%) | 0% | 9.6 | 195,823 | Ordinary Shares |
| Theravance Biopharma Inc | Richard A. Graham | SVP, Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Dec 2021 | 240,000 | 409,061 (0%) | 0% | 0 | Ordinary Shares | |
| Theravance Biopharma Inc | Richard A. Graham | SVP, DEVELOPMENT | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.36 per share. | 19 Nov 2021 | 4,263 | - | 0% | 8.4 | 35,639 | Ordinary Shares |
| Theravance Biopharma Inc | Richard A. Graham | SVP, Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.05 per share. | 20 Aug 2021 | 6,819 | 173,205 (0%) | 0% | 14.1 | 95,807 | Ordinary Shares |
| Theravance Biopharma Inc | Richard A. Graham | SVP, Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.80 per share. | 20 May 2021 | 3,410 | 180,024 (0%) | 0% | 17.8 | 60,698 | Ordinary Shares |
| Theravance Biopharma Inc | Richard A. Graham | SVP, Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 18.79 per share. | 20 Feb 2021 | 6,597 | 182,152 (0%) | 0% | 18.8 | 123,958 | Ordinary Shares |
| Theravance Biopharma Inc | Richard A. Graham | SVP, Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2021 | 65,000 | 188,749 (0%) | 0% | 0 | Ordinary Shares | |
| Theravance Biopharma Inc | Richard A. Graham | SVP, Development | Sale of securities on an exchange or to another person at price $ 19.47 per share. | 14 Dec 2020 | 7,500 | 123,749 (0%) | 0% | 19.5 | 146,058 | Ordinary Shares |
| Theravance Biopharma Inc | Richard A. Graham | SVP, Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.21 per share. | 20 Nov 2020 | 3,876 | 131,249 (0%) | 0% | 17.2 | 66,706 | Ordinary Shares |
| Theravance Biopharma Inc | Richard A. Graham | SVP, Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Sep 2020 | 27,500 | 135,125 (0%) | 0% | 0 | Ordinary Shares | |
| Theravance Biopharma Inc | Richard A. Graham | SVP, Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 18.22 per share. | 20 Aug 2020 | 6,598 | 107,625 (0%) | 0% | 18.2 | 120,216 | Ordinary Shares |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges